Table 3.
Properties of pharmacologically isolated AMPA receptor- and NMDA receptor-mediated EPSCs
| Type 1 | Type 2 | P Value | |
|---|---|---|---|
| With NMDA receptor antagonist | |||
| AMPA at −70 mV | |||
| AMPA amplitude, pA | 491 ± 102 (n = 8) | 300 ± 56 (n = 7) | 0.14048 |
| AMPA 10–90% rise time, ms* | 0.39 ± 0.02 (n = 8) | 0.51 ± 0.04 (n = 7) | 0.02029 |
| AMPA half-width, ms* | 1.36 ± 0.18 (n = 8) | 2.04 ± 0.20 (n = 7) | 0.02528 |
| AMPA 90–10% decay time, ms* | 3.26 ± 0.53 (n = 8) | 5.46 ± 0.67 (n = 7) | 0.02209 |
| AMPA Aslow, pA | 48 ± 18 (n = 8) | 24 ± 5 (n = 7) | 0.23807 |
| AMPA Afast, pA | 403 ± 82 (n = 8) | 255 ± 51 (n = 7) | 0.16371 |
| AMPA %slow | 10.2 ± 2.3 (n = 8) | 10.0 ± 2.4 (n = 7) | 0.95168 |
| AMPA τslow, ms* | 5.95 ± 0.96 (n = 8) | 15.70 ± 3.53 (n = 7) | 0.01414 |
| AMPA τfast, ms | 1.14 ± 0.20 (n = 8) | 1.71 ± 0.17 (n = 7) | 0.05516 |
| AMPA τD,W, ms** | 1.58 ± 0.26 (n = 8) | 2.74 ± 0.25 (n = 7) | 0.00769 |
| gAMPA | |||
| gAMPA (nS) | 6.96 ± 1.96 (n = 6) | 3.95 ± 1.35 (n = 4) | 0.29410 |
| With AMPA receptor antagonist | |||
| NMDA at +30 mV | |||
| NMDA amplitude, pA | 130 ± 25 (n = 15) | 134 ± 78 (n = 4) | 0.94232 |
| NMDA 10–90% rise time, ms | 4.01 ± 0.55 (n = 15) | 4.66 ± 1.02 (n = 4) | 0.59376 |
| NMDA half-width, ms | 35.97 ± 2.13 (n = 15) | 41.90 ± 6.80 (n = 4) | 0.27939 |
| NMDA 90–10% decay time, ms | 136.35 ± 7.79 (n = 15) | 169.10 ± 34.21 (n = 4) | 0.16093 |
| NMDA τD,W, ms | 75.65 ± 3.77 (n = 15) | 79.29 ± 14.12 (n = 4) | 0.72018 |
| gNMDA | |||
| gmax NMDA, nS | 5.49 ± 0.90 (n = 16) | 5.46 ± 2.73 (n = 4) | 0.98914 |
| KMg, mM | 1.37 ± 0.15 (n = 16) | 1.69 ± 0.23 (n = 4) | 0.32608 |
| δ | 0.82 ± 0.01 (n = 16) | 0.88 ± 0.03 (n = 4) | 0.09857 |
| V0.5, mV | −8.56 ± 1.98 (n = 16) | −12.57 ± 2.07 (n = 4) | 0.34702 |
| γ, mV | 16.01 ± 0.30 (n = 16) | 14.97 ± 0.46 (n = 4) | 0.12181 |
All data are means ± SE. Control conditions are shown. Statistical significance was calculated using an independent Student's t-test.
*
P < 0.05;
**
P < 0.01;
***
P < 0.001.